Literature DB >> 27167632

[Weakness of the extremities in a 73-year-old male patient].

M Attaran-Bandarabadi1, P Kalbasi Anaraki2, W Gwinner3, H Haller3.   

Abstract

A patient undergoing cyclosporine therapy presented with muscle weakness. This was preceded by diarrhea and treated with ciprofloxacin. Rhabdomyolysis was diagnosed clinically and biochemically. This was presumably drug-induced triggered by a combined therapy with cyclosporine, amlodipine, simvastatin and ciprofloxacin. The case presented demonstrates that during therapy with several substances which inhibit the degradation of simvastatin, the additional administration of ciprofloxacin should be considered with extreme caution.

Entities:  

Keywords:  Amlodipine; Ciprofloxacin; Cyclosporin; Rhabdomyolysis; Simvastatin

Mesh:

Substances:

Year:  2016        PMID: 27167632     DOI: 10.1007/s00108-016-0060-8

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  13 in total

1.  Rhabdomyolysis and acute kidney injury secondary to interaction between simvastatin and cyclosporine.

Authors:  Rosalia Viviana Scarfia; Anna Clementi; Antonio Granata
Journal:  Ren Fail       Date:  2013-08       Impact factor: 2.606

Review 2.  Rhabdomyolysis and acute kidney injury.

Authors:  Xavier Bosch; Esteban Poch; Josep M Grau
Journal:  N Engl J Med       Date:  2009-07-02       Impact factor: 91.245

3.  Mild rhabdomyolysis after renal transplantation.

Authors:  Shoichi Iida; Hideki Ishida; Naoshi Miyamoto; Hiroki Shirakawa; Tomokazu Shimizu; Kiyoshi Setoguchi; Daisuke Toki; Kazunari Tanabe
Journal:  Saudi J Kidney Dis Transpl       Date:  2011-05

4.  Statin-induced rhabdomyolysis: a comprehensive review of case reports.

Authors:  Polyana Mendes; Priscila Games Robles; Sunita Mathur
Journal:  Physiother Can       Date:  2014       Impact factor: 1.037

5.  The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, and not CYP2D6.

Authors:  Thomayant Prueksaritanont; Bennett Ma; Nathan Yu
Journal:  Br J Clin Pharmacol       Date:  2003-07       Impact factor: 4.335

Review 6.  The syndrome of rhabdomyolysis: complications and treatment.

Authors:  Yiannis S Chatzizisis; Gesthimani Misirli; Apostolos I Hatzitolios; George D Giannoglou
Journal:  Eur J Intern Med       Date:  2008-04-28       Impact factor: 4.487

7.  Development of a pharmacokinetic interaction model for co-administration of simvastatin and amlodipine.

Authors:  Hankil Son; Donghwan Lee; Lay Ahyoung Lim; Seong Bok Jang; Hyerang Roh; Kyungsoo Park
Journal:  Drug Metab Pharmacokinet       Date:  2013-08-20       Impact factor: 3.614

Review 8.  Rhabdomyolysis: review of the literature.

Authors:  R Zutt; A J van der Kooi; G E Linthorst; R J A Wanders; M de Visser
Journal:  Neuromuscul Disord       Date:  2014-05-21       Impact factor: 4.296

9.  Severe rhabdomyolysis associated with simvastatin and role of ciprofloxacin and amlodipine coadministration.

Authors:  Nicolas De Schryver; Xavier Wittebole; Peter Van den Bergh; Vincent Haufroid; Eric Goffin; Philippe Hantson
Journal:  Case Rep Nephrol       Date:  2015-03-26

Review 10.  Pharmacokinetic drug-drug interactions between 1,4-dihydropyridine calcium channel blockers and statins: factors determining interaction strength and relevant clinical risk management.

Authors:  Yi-Ting Zhou; Lu-Shan Yu; Su Zeng; Yu-Wen Huang; Hui-Min Xu; Quan Zhou
Journal:  Ther Clin Risk Manag       Date:  2013-12-20       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.